IBSA launches Hyaluxelle in the UK for GSM-related Vulvovaginal symptoms
Published: 11 Mar 2026
Author: Precedence Research
IBSA has launched Hyaluxelle in the United Kingdom, a non-hormonal injectable to relieve vulvovaginal symptoms linked to genitourinary syndrome of Menopause (GSM). The treatment involves hyaluronic acid, which has the ability to retain moisture and support tissue hydration. It is developed to treat vaginal dryness, burning, itching and pain by restoring moisture and elasticity in the tissue. This treatment is an alternative for those who are unable or unwilling to use hormonal options.
Non-Hormonal Treatment Options for GSM
Genitourinary syndrome of Menopause (GSM) is a chronic condition that occurs due to oestrogen deficiency, associated with chronic vulvovaginal and lower urinary tract symptoms. These symptoms rarely disappear without proper treatment. Studies suggest that around half of post-menopausal women experience GSM but remain untreated. One of the common symptoms is vulvovaginal atrophy. The reduced oestrogen leads to dryness, irritation, altered vaginal pH and pain during intercourse. These symptoms often affect emotional well-being, intimate relationships, and quality of life.
Hyaluxelle is a non-hormonal injectable treatment developed using IBSA’s patented NAHYCO Hybrid Technology, which combines high- and low-molecular weight hyaluronic acid. The formulation is designed to improve elasticity and support tissue hydration. In the UK, the highest hyaluronic acid concentration is available.
Hyaluxelle is administered via intradermal injection in the vulvar vestibule, in two sessions apart by a month. Its moisturising and viscoelasticity property helps to rehydrate the tissue and encourage repair by supporting collagen and elastin production. Study indicates improvement in GSM-related vulvovaginal symptoms. Histological examination has shown an increase in thickness and reduced inflammation following treatment.
According to Precedence Research, the genitourinary syndrome of menopause (GSM) market size accounted for USD 1.60 billion in 2025 and is predicted to increase from USD 1.72 billion in 2026 to approximately USD 3.21 billion by 20345, expanding at a CAGR of 7.20% from 2026 to 2035 as demand grows due to rising awareness of menopausal health across the world.
Growing Focus on Women’s Health
The introduction of Hyaluxelle highlights the rising attention given to women’s health and menopause management in the healthcare market. The IBSA is expanding its presence in the healthcare market by launching Hyaluxelle for genitourinary syndrome of Menopause (GSM)-related vulvovaginal symptoms. This shows companies are investing in the developing solutions for conditions that directly affects quality of life for women.
A recent report by Precedence Research highlights that the genitourinary syndrome of menopause (GSM) market is benefiting from rising awareness and increasing attention to women’s health.